The Discovery of Jan Van Deursen is an exciting breakthrough in the field of aging research. Born in the Netherlands, Jan Van Deursen completed his Ph.D. in cell biology at the University of Nijmegen in 1993. After compl
The Discovery of Jan Van Deursen is an exciting breakthrough in the field of aging research. Born in the Netherlands, Jan Van Deursen completed his Ph.D. in cell biology at the University of Nijmegen in 1993. After completing his training in the Netherlands, he moved to the US to pursue his dream of advancing stem cell editing techniques in mice. In 1999, he moved to the Mayo Clinic to lead its transgenic and gene knockout core facility. He was hired to direct this world-renowned center for research in the Mayo Clinic, where he served for eight years.
The groundbreaking research was led by Dr. Jan M. van Deursen, the scientific co-founder of Unity Biotechnology. The company develops compounds to eliminate senescent cells. Jan Van Deursen co-invented the technology, and the Mayo Clinic licensed the company.
After publishing his watershed papers in Science, Nature, and Cell, Jan Van Deursen moved to the Mayo Clinic in Rochester, Minnesota. Drs recruited him. Rick Bram and Bill Crist soon accepted a position at the Mayo Clinic. The Mayo Clinic is a progressive institution, and Dr. Jan van Deursen found the right environment for his research. The Mayo Clinic is committed to collaborating with basic science labs.
His research team also benefits from a network of clinical colleagues. He helped develop mouse models that mimic many human diseases. His work also led to an important breakthrough in aging. Age-related senescent cells are accumulated in the body. These cells lose their original function and fail to die. In Dr. Childs' lab, the scientists have developed methods to identify how to remove them. These studies are the next step in preventing age-related diseases.
In 2009, Dr. Van Deursen applied his discoveries to cancer research. His latest discovery - the discovery of BubR1, a vital mitotic checkpoint protein - has been implicated in age-related cancers, progeria, and aging. It is also known that a decrease in these cells' levels during adulthood prevents cancer development. The Mayo team has applied these findings to clinical trials.
After studying the effects of senolytics, Jan van Deursen is more optimistic than ever. In addition to the super-aged mice, his lab has also made other experiments in which the removal of senescent cells delayed the deterioration of aging organs. Furthermore, the scientists found that destroying the cells delayed the development of age-related diseases and extended animals' median lifespan by 25 percent.
In 1999, Dr. van Deursen earned his doctorate in cell biology from the Netherlands. He came to the Mayo Clinic in the United States to research cancer. After creating mouse models prone to chromosome abnormalities, his research focused on senescent cells. These cells slowly degrade tissue and organ function and deteriorate organ health. Dr. Van Deursen and his team continued to study the mice and found promising results from these experiments.
Despite his early success, Jan van Deursen is a leading figure in the field of aging research. He developed a mouse model engineered to kill senescent cells and extend the mice's lifespan. His findings are already leading to new treatments for age-related diseases. He is now putting his research into action by founding a new company, Unity Biotechnology. This innovative new company will take its discovery from the lab bench to the bedside of patients.
While he has made a name for himself in the world of molecular biology, he has not forgotten his personal life. He is now co-founder of Unity Biotechnology, a publicly traded company with the mission to develop therapeutics to reverse human aging, with an initial focus on age-related diseases. Van Deursen is a married man who lives in Rochester, Minnesota. He and his wife have been married for over 25 years.
If you looking Business Insurance Agency in Rochester NY so you can consult with GGIANY.COM for further information across USA
Can’t donate? Please share. Even a quick share on Facebook can help.
The average share raises $97.